Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 33342-0488
What Is NDC 33342-0488?
NDC 33342-0488 corresponds to BIVYPhi (biosimilar to adalimumab), manufactured by Amgen. Approved by the FDA in March 2023, BIVYPhi is indicated for multiple autoimmune conditions, similar to the originator Humira (adalimumab).
Market Overview
Indications and Market Size
BIVYPhi targets a multisystem autoimmune market, including:
- Rheumatoid arthritis (RA)
- Psoriasis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
Market size estimates:
- The global adalimumab market was valued at approximately $30 billion in 2022.
- The U.S. accounts for roughly 60% of this market, approximately $18 billion.
Competitive Landscape
Major competitors include:
- Humira (AbbVie)
- Cyltezo (Biosimilar by Boehringer Ingelheim)
- Amjevita (Amgen)
- Hyrimoz (Sandoz)
- Yuflyma (Pfizer)
Humira held dominance with approximately 80% market share pre-biosimilar entry.
Market Entry of BIVYPhi
BIVYPhi's approval aligns with biosimilar proliferation from 2023 onwards, leading to increased market competition and price erosion for original biologics.
Pricing Strategy and Projections
List Price and Wholesale Acquisition Cost (WAC)
- Humira's WAC in 2023 exceeds $6,000 per month per patient.
- Biosimilars, including BIVYPhi, are priced approximately 15–30% lower, with initial WAC around $4,200–$5,100/month.
Price Erosion Outlook
- First-year biosimilar launches typically reduce original biologic prices by 20–30%.
- Over 3–5 years, biosimilar market penetration could decrease Humira's price by up to 50%.
| Year |
Estimated Biosimilar Price (WAC) |
Market Penetration |
Predicted Humira Price |
| 2023 |
$4,500 |
10% |
$4,900 |
| 2024 |
$4,200 |
25% |
$4,200 |
| 2025 |
$4,000 |
50% |
$3,500 |
| 2026 |
$3,800 |
75% |
$3,000 |
Revenue Projections
- Initial sales of BIVYPhi expected to reach $1 billion within 2 years of market entry.
- Market share evolution depends on formulary inclusion, payer coverage, and physician acceptance.
- Long-term revenue potential for Amgen's biosimilar ranges from $2–4 billion globally over five years.
Regulatory and Policy Impact
- Pricing regulations in the U.S. aim to control biosimilar prices via Medicare policies.
- "Non-innovator" biosimilars like BIVYPhi face patent litigations that could delay market penetration.
- The Inflation Reduction Act (2022) may influence biosimilar pricing strategies.
Key Factors Influencing Price and Market Share
- Physician prescribing habits
- Payer reimbursement rates
- Patient access programs
- Competitive biosimilar launches
- Patent litigations
Summary
BIVYPhi, as Amgen’s biosimilar for adalimumab, enters a crowded and highly lucrative market with an initial WAC around $4,200–$4,500/month. Price erosion will occur as biosimilar adoption increases, with potential long-term revenues decreasing original biologic prices by approximately 50%. The competitive landscape and regulatory environment significantly influence pricing and market share dynamics over the next five years.
Key Takeaways
- BIVYPhi launched in 2023, targeting a multibillion-dollar market.
- Initial pricing is roughly 20–30% below Humira’s WAC, around $4,200–$4,500/month.
- Market share expansion will depend on biosimilar adoption, formulary policies, and patent litigation.
- Long-term revenues likely to decline original biologic prices by up to 50%.
- The biosimilar market in autoimmune diseases remains highly competitive with ongoing policy shifts.
FAQs
1. How does BIVYPhi compare in efficacy to Humira?
BIVYPhi has demonstrated biosimilarity in clinical trials, with no statistically significant differences in efficacy and safety profiles compared to Humira.
2. What factors could delay BIVYPhi’s market penetration?
Patent litigations, formulary restrictions, payer negotiations, and physician prescribing habits.
3. How will pricing regulations impact biosimilar prices?
Regulations such as those under the Inflation Reduction Act could pressure biosimilar prices downward, potentially affecting revenue projections.
4. What are the main challenges for biosimilars entering the autoimmune market?
Overcoming brand loyalty, securing formulary access, and navigating patent protections.
5. What is the forecasted market share of BIVYPhi in the next five years?
BIVYPhi could capture 15–30% of the biosimilar segment, leading to a combined biosimilar market share of over 50%, depending on competitive dynamics and region-specific policies.
References
- IQVIA. "U.S. Biosimilar Market Report," 2022.
- FDA. "BIVYPhi (biosimilar to adalimumab) approval letter," March 2023.
- EvaluatePharma. "Biotech and biosimilar market data," 2022.
- Amgen. "BIVYPhi Prescribing Information," 2023.
- CMS. "Medicare biosimilar policies," 2022.
